SCHEMBL3154182

SCHEMBL3154182

O=C(NCc1ccc(C(F)(F)F)cc1)c1ccc(S(=O)(=O)Nc2ccon2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 3/20 0.61
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
LMNA P02545 2/20 0.56
NPSR1 Q6W5P4 2/20 0.49
HTT P42858 1/20 0.49
LSS P48449 1/20 0.49
EPHX2 P34913 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPK14 Q16539 1/20 0.47
PPARA Q07869 1/20 0.47
NR1H4 Q96RI1 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
KDM1A O60341 1/20 0.46
HDAC1 Q13547 1/20 0.46
NAMPT P43490 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3169627 0.83 SCN3A (0.59) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3162392 0.80 MAPT (0.63) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3258459 0.80 SCN3A (0.63) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3163597 0.80 SCN3A (0.66) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3167975 0.79 SCN3A (0.59) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3163135 0.79 SCN3A (0.59) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL12010898 0.79 MAPT (0.80) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3174028 0.78 SCN3A (0.63) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3159479 0.78 P2RY1 (0.67) SCN3AMAPTKMT2AMEN1LMNA
SCHEMBL3153875 0.78 SCN3A (0.61) SCN3AMAPTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885KMT2A 1920/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885KMT2A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.